James J Vredenburgh - JoVE Visualize

Showing results (41-50 of 102) with videos related to

Pageof 11

Sort By:

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2005

Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancerWilliam P Petros, Penelope J Hopkins, Susan Spruill, et al.

The American Journal of Surgical Pathology|May 29, 2004

Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantationMatthew J Snyder, Timothy T Stenzel, Patrick J Buckley, et al.

Journal of Neuro-Oncology|July 12, 2011

Phase I study of sunitinib and irinotecan for patients with recurrent malignant gliomaDavid A Reardon, James J Vredenburgh, April Coan, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2008

Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecanSith Sathornsumetee, Yiting Cao, Jennifer E Marcello, et al.

Cancer|February 28, 2009

Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant gliomaDavid A Reardon, Merrill J Egorin, Annick Desjardins, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2004

Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancerYago Nieto, James J Vredenburgh, Elizabeth J Shpall, et al.

Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 9, 2016

Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ)Mary Lou Affronti, Sarah Woodring, Karen Allen, et al.

Journal of Neuro-Oncology|February 13, 2009

Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testingLee W Jones, Rachel-Rose Cohen, Stephanie K Mabe, et al.

Expert Review of Anticancer Therapy|May 13, 2008

Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant gliomaRichard G Everson, Michael W Graner, Matthias Gromeier, et al.

Journal of Neuro-Oncology|June 18, 2009

Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapyJennifer A Quinn, Sara Xiaoyin Jiang, David A Reardon, et al.

Pageof 11

Showing results (41-50 of 102) with videos related to

Sort By:

Pageof 11

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2005

Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancerWilliam P Petros, Penelope J Hopkins, Susan Spruill, et al.

The American Journal of Surgical Pathology|May 29, 2004

Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantationMatthew J Snyder, Timothy T Stenzel, Patrick J Buckley, et al.

Journal of Neuro-Oncology|July 12, 2011

Phase I study of sunitinib and irinotecan for patients with recurrent malignant gliomaDavid A Reardon, James J Vredenburgh, April Coan, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2008

Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecanSith Sathornsumetee, Yiting Cao, Jennifer E Marcello, et al.

Cancer|February 28, 2009

Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant gliomaDavid A Reardon, Merrill J Egorin, Annick Desjardins, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2004

Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancerYago Nieto, James J Vredenburgh, Elizabeth J Shpall, et al.

Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 9, 2016

Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ)Mary Lou Affronti, Sarah Woodring, Karen Allen, et al.

Journal of Neuro-Oncology|February 13, 2009

Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testingLee W Jones, Rachel-Rose Cohen, Stephanie K Mabe, et al.

Expert Review of Anticancer Therapy|May 13, 2008

Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant gliomaRichard G Everson, Michael W Graner, Matthias Gromeier, et al.

Journal of Neuro-Oncology|June 18, 2009

Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapyJennifer A Quinn, Sara Xiaoyin Jiang, David A Reardon, et al.

Pageof 11